Top section
Top section
◆ Have capital markets comprehended the heatwave? ◆ Which SSA issuers need to get it done this autumn ◆ Halcyon days for MTN, M&A and ECM bankers
Investors pay little heed to alarming worsening of climate
New $75m partnership to develop treatment for lymphoma was “catalyst for investors”
More articles
More articles
More articles
-
Equity capital markets bankers are in discussions with European governments about privatisations of state assets, but political upheaval has blocked several projects. Politicians are nervous of damaging headlines if they sell assets to the market. -
Equity investors have made solid returns so far in 2019, but many are wary about the pricing of European IPOs, where some sellers look like having high expectations.
-
A surge in shareholder activism is providing banks with a lucrative new source of revenue, but they have to tread carefully or risk losing treasured corporate relationships, writes David Rothnie.
-
Sterling and Wilson Solar, the solar power business of Indian conglomerate Shapoorji Pallonji Group, is eyeing a listing of up to Rp45bn ($648m), having filed a draft prospectus this week.
-
Hutchison China MediTech sparked life into the Hong Kong biotechnology IPO market this week, filing a draft prospectus for a $500m listing with the city’s stock exchange. The globally known name — already listed on two foreign exchanges — is a boost for biotech investors, who have been drip-fed smaller start-ups since Hong Kong allowed pre-revenue companies from the sector to begin listing last year. Jonathan Breen reports.
-
The Shanghai Stock Exchange (SSE) has published guidelines for companies looking to list on its new Science and Technology Innovation Board, as well as underwriters, including an unusual requirement for the sponsors of initial public offerings (IPOs) to commit to deals.
Sub-sections
shared comment list
